PBYI - Puma Biotechnology Summary, Stock Quote and News

Market Overview

10.86 0.16 (1.5%)

Data as of Mar 06, 2021

Prev. Close 10.7
Price Open 10.78
Volume 424,228
Day's Range 10.01 - 10.88
52 Wk Range 5.5 - 14.14
50 Day Moving Avg. 11.36
PE Ratio
Shares Outstanding 40.26M
Market Cap 437.21M

Trade PBYI stock for free with recommended broker TD Ameritrade.

Analyst Rating View All Ratings

Date	Research Firm	Action	Current	Target
8/10/20	Citigroup	Maintains	Neutral	12.0
8/07/20	SVB Leerink	Maintains	Market Perform	10.0
6/25/20	B of A Securities	Reinstates	Underperform	9.0

Puma Biotechnology Q4 Adj. EPS $(0.14) Beats $(0.29) Estimate, NERLYNX Sales $50.00M Miss $52.79M Estimate Benzinga NewsdeskThu, 25 Feb 2021 16:48:51 -0500
Puma Biotechnology Presents Interim Results From Phase II SUMMIT Trial Of Neratinib For EGFR Exon 18-Mutated, Metastatic Non-Small Cell Lung Cancer At WCLC 2020 Benzinga NewsdeskFri, 29 Jan 2021 08:09:00 -0500
Puma Biotechnology Presents Interim Results From Biliary Tract Cancers Cohort Of Phase II SUMMIT 'Basket' Trial Of Neratinib At ASCO GI Benzinga NewsdeskFri, 15 Jan 2021 08:25:06 -0500
Celcuity Reports Clinical Trial Collaboration With Massachusetts General Hospital, Puma Biotech To Conduct Phase 2 Trial Benzinga NewsdeskWed, 23 Dec 2020 07:07:52 -0500
Puma Biotechnology Presents Efficacy And Safety Outcomes From The Phase III NALA Trial At The 2020 SABCS Benzinga NewsdeskFri, 11 Dec 2020 14:01:19 -0500
Puma Biotechnology Presents Updated Results From Phase II SUMMIT Trial Of Neratinib For HER2-Mutant, HR-Positive Metastatic Breast Cancer At SABCS 2020 Benzinga NewsdeskWed, 09 Dec 2020 17:07:24 -0500
Puma Biotechnology Says Has Prevailed In Proceedings Against European EP Patent 1848414; European Board Of Appeals Rejected Opposition Of Patent By A Boehringer Ingelheim Entity Benzinga NewsdeskWed, 02 Dec 2020 08:34:26 -0500
Puma Biotechnology To Present Neratinib Data At San Antonio Breast Cancer Symposium Benzinga NewsdeskTue, 17 Nov 2020 16:16:02 -0500
Puma Biotechnology shares are trading lower after the company reported worse-than-expected Q3 EPS and sales results. Benzinga NewsdeskFri, 06 Nov 2020 07:58:23 -0500
Puma Biotechnology Q3 EPS $(0.79) Misses $(0.39) Estimate, Sales $50.80M Miss $53.05M Estimate Benzinga NewsdeskThu, 05 Nov 2020 16:47:19 -0500
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Polyphor Announces Financial Results for the Full-Year 2020 Globe Newswire1 day ago
Puma Biotechnology to Present at the Barclays Global Healthcare Conference Business Wire1 day ago
Puma Biotechnology to Present at the H.C. Wainwright Global Life Sciences Conference Business Wire3 days ago
CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration Business WireFeb 25, 2021
Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China Business WireFeb 25, 2021
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results Business WireFeb 25, 2021
Puma Biotechnology, Inc. to Host Earnings Call ACCESSWIREFeb 25, 2021
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2020 Financial Results Business WireFeb 11, 2021
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business WireFeb 09, 2021
Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18-Mutated, Metastatic Non-Small Cell Lung Cancer at WCLC 2020 Business WireJan 29, 2021
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Puma Biotechnology and CANbridge terminate NERLYNX license agreement Seeking AlphaFeb 26, 2021
Puma Biotechnology's (PBYI) CEO Alan Auerbach on Q4 2020 Results - Earnings Call Transcript Seeking AlphaFeb 25, 2021
Puma Biotechnology and Pierre Fabre amend NERLYNX license agreement Seeking AlphaFeb 25, 2021
Puma Bio up 6% after reporting neratinib data in lung cancer Seeking AlphaJan 29, 2021
Puma Bio's neratinib shows encouraging effect in biliary tract cancers Seeking AlphaJan 15, 2021
Puma Biotechnology: Waiting For Commercial Numbers To Catch Up To Clinical Data Seeking AlphaDec 29, 2020
Puma Biotech's neratinib shows improved CNS outcomes in late-stage breast cancer study Seeking AlphaDec 11, 2020
Puma Bio's neratinib meaningful reduces risk of recurrence and improves survial in early stage breast cancer patients Seeking AlphaDec 10, 2020
Puma Biotechnology says European patent board upholds patent covering EGFR inhibitors Seeking AlphaDec 02, 2020
Puma Biotechnology's (PBYI) CEO Alan Auerbach on Q3 2020 Results - Earnings Call Transcript Seeking AlphaNov 05, 2020
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Earnings View Earnings

Q4 2020	EST	Actual	Surprise
EPS:	-0.290	-0.140	0.1500
Rev:	52.79M	52.60M	-190.00K

Q1 2021	EST	Actual	Surprise
EPS:	Expected 2021-05-06
Rev:	Expected 2021-05-06

Start Investing

The Best Online Stock Trading Brokers

Best Free Stock Trading Brokers

Best Forex Brokers

Best Futures Brokers

How to Invest in Real Estate

Best Day Trading Courses

+

+

Market Overview

Tickers

Articles

Keywords

Puma Biotechnology PBYI:NASDAQ

Analyst Rating View All Ratings

Earnings View Earnings

Start Investing